<DOC>
	<DOCNO>NCT00572455</DOCNO>
	<brief_summary>To evaluate safety efficacy PF-04217329 .</brief_summary>
	<brief_title>Safety Efficacy PF-04217329 Patients With Glaucoma Elevated Eye Pressure .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Diagnosis primary openangle glaucoma ( include pigmentary pseudoexfoliative ) ocular hypertension 1 eye . Qualifying intraocular pressure ( IOP ) eye Eligibility 1 2 measurement . Closed/barely open anterior chamber angle history acute angle closure either eye . Anticipate need initiate modify medication ( systemic topical ) know affect intraocular pressure ( IOP ) study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>